| Field | Specification |
|---|---|
| Mfr No | |
| Species |
A2780 is a human ovarian cancer cell line that was first established in 1972 from a patient with advanced epithelial ovarian cancer. The cells were characterized as being sensitive to cisplatin and doxorubicin, two commonly used chemotherapy drugs for ovarian cancer. Since its establishment, A2780 has been widely used in cancer research studies, particularly in the development and testing of new cancer treatments.
Research using A2780 cells has provided valuable insights into the biology of ovarian cancer, including the identification of specific genetic mutations such as TP53 and BRCA1. These mutations are associated with increased risk of ovarian cancer and are also found in other types of cancer.
Additionally, A2780 cells have been used to study the role of angiogenesis, the process by which new blood vessels form, in ovarian cancer progression and to evaluate the efficacy of anti-angiogenic drugs. Angiogenesis plays a critical role in the growth and progression of ovarian cancer as it provides oxygen and nutrients for the cancer cells to grow.
Studies using A2780 cells have demonstrated the overexpression of pro-angiogenic factors such as VEGF and angiopoietin-2, which promote the formation of new blood vessels. Additionally, A2780 cells have been used to test the efficacy of anti-angiogenic drugs such as bevacizumab, which target VEGF and inhibit the formation of new blood vessels.
Furthermore, A2780 cells have been used to evaluate the efficacy of various therapeutic agents, including chemotherapy drugs, targeted therapies such as PARP inhibitors, and immunotherapies.
In particular, A2780 cells have been used to study the effect of different drug combinations on cancer cell proliferation, apoptosis, and drug resistance. Overall, the A2780 cell line has played a significant role in the advancement of ovarian cancer research, providing a valuable tool for understanding the disease and developing new treatments.
—
- cultureMedium: RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a)
- supplements: Supplement the medium with 10% FBS
- dissociationReagent: Accutase
- subculturing: Gather the suspension cells in a 15 ml tube and gently wash the adherent cells with PBS lacking calcium and magnesium (use 3-5 ml for T25 flasks and 5-10 ml for T75 flasks). Apply Accutase (1-2 ml for T25 flasks, 2.5 ml for T75 flasks) ensuring full coverage of the cell layer. Allow the cells to incubate at room temperature for 10 minutes. Following incubation, combine and centrifuge both the suspension and adherent cells. After centrifugation, carefully resuspend the cell pellet and transfer the cell suspension into new flasks containing fresh medium.
- fluidRenewal: 2 to 3 times per week
- freezeMedium: As a cryopreservation medium, use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress.
- Flowers and Leaves of Artemisia absinthium and Artemisia annua Phytochemical Characterization, Anti-Inflammatory, Antioxidant, and Anti-Proliferative Activities Evaluation
- Prognostic significance of the estrogen receptor beta (ERβ) isoforms ERβ1, ERβ2, and ERβ5 in advanced serous ovarian cancer.
- Tetrazolylidene-Stabilized Gold(I) Complexes: Synthesis and Evaluation of Anticancer Activity In Vitro .
- Flowers and Leaves of Artemisia absinthium and Artemisia annua Phytochemical Characterization, Anti-Inflammatory, Antioxidant, and Anti-Proliferative Activities Evaluation.
- Single cell resolution in vivo imaging of DNA damage following PARP inhibition
- Design, synthesis and biological evaluation of (±)-kusunokinin derivatives as potent anticancer agents.
- Nilotinib reduced the viability of human ovarian cancer cells via mitochondria-dependent apoptosis, independent of JNK activation.
10%
OFF
15%OFF
20%
OFF
$50
OFF
FREE
SAMPLE
